Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of AMG 145 (evolocumab) in primary hyperlipidaemia and mixed dyslipidaemia
2012-004357-83Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, combined dyslipidaemia, lipid disorder, sponsored by Amgen. Started Apr 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiacombined dyslipidaemialipid disorder
Beyond the preview
Go deeper on 2012-004357-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004357-83.